M Ventures: pharma CVC and biotech innovation in 2026

January 9, 2026

35 min episode · 2 min read

M Ventures

Episode

35 min

Read time

2 min

Topics

Product & Tech Trends

AI-Generated Summary

Published Mar 14, 2026

Key Takeaways

✓CVC Dual Mandate: Corporate venture funds like M Ventures operate under two simultaneous obligations — strategic optionality for the parent company and institutional-grade financial returns. Investments begin with a strategic rationale but can migrate to pure financial assets if Merck's strategy shifts, ensuring the fund recycles returns into the next generation of bets.
✓Spinout Validation Structure: When spinning assets out of a pharma parent, M Ventures acts as sole seed investor for up to two years, funding only the critical validation experiments before syndicating externally. This approach signals commitment to outside investors, removes the "skeleton in the cupboard" perception, and de-risks the program before a broader Series A.
✓Pitch Clarity Framework: Founders pitching corporate VCs should structure their narrative backwards from a defined target product profile — stating the end product, the cash required, the timeline, and the specific hurdles. Reaching that core message quickly matters more than comprehensive detail, given the volume of information competing for investor attention today.
✓2026 Therapeutic Priorities: M Ventures will continue deploying into oncology, autoimmune, neurology, and fertility while expanding into phase one and phase two stage companies as first investments — a remit previously limited to preclinical. Genetically defined diseases with manageable late-stage trial costs and a visible shift from oncology toward immunology are the directional signals to watch.
✓Financing Environment Realism: The biotech funding environment remains constrained entering 2026, with public market recovery expected only toward year-end. Companies that have not delivered meaningful clinical or platform milestones within their current round face longer, harder fundraising cycles. Rising M&A activity is a leading indicator of returning confidence, but early-stage deployment remains selective.

What It Covers

Hakan Goker, Managing Director at M Ventures — Merck KGaA's €600 million corporate venture arm — outlines how pharma CVC operates across healthcare, life science tools, and electronics, while sharing 2025 portfolio highlights and investment priorities heading into 2026 across oncology, autoimmune, neurology, and fertility.

Key Questions Answered

•CVC Dual Mandate: Corporate venture funds like M Ventures operate under two simultaneous obligations — strategic optionality for the parent company and institutional-grade financial returns. Investments begin with a strategic rationale but can migrate to pure financial assets if Merck's strategy shifts, ensuring the fund recycles returns into the next generation of bets.
•Spinout Validation Structure: When spinning assets out of a pharma parent, M Ventures acts as sole seed investor for up to two years, funding only the critical validation experiments before syndicating externally. This approach signals commitment to outside investors, removes the "skeleton in the cupboard" perception, and de-risks the program before a broader Series A.
•Pitch Clarity Framework: Founders pitching corporate VCs should structure their narrative backwards from a defined target product profile — stating the end product, the cash required, the timeline, and the specific hurdles. Reaching that core message quickly matters more than comprehensive detail, given the volume of information competing for investor attention today.
•2026 Therapeutic Priorities: M Ventures will continue deploying into oncology, autoimmune, neurology, and fertility while expanding into phase one and phase two stage companies as first investments — a remit previously limited to preclinical. Genetically defined diseases with manageable late-stage trial costs and a visible shift from oncology toward immunology are the directional signals to watch.
•Financing Environment Realism: The biotech funding environment remains constrained entering 2026, with public market recovery expected only toward year-end. Companies that have not delivered meaningful clinical or platform milestones within their current round face longer, harder fundraising cycles. Rising M&A activity is a leading indicator of returning confidence, but early-stage deployment remains selective.

Notable Moment

Hakan Goker describes how M Ventures maintains a formal firewall with Merck's BD team — actively directing portfolio companies to speak directly with BD rather than acting as intermediary — arguing that premature involvement creates conflicts that damage both the small company and the parent's reputation.

Know someone who'd find this useful?